An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
PHASE1CompletedINTERVENTIONAL
Enrollment
10
Participants
Timeline
Start Date
October 31, 2003
Study Completion Date
August 31, 2005
Conditions
Wegener's Granulomatosis
Interventions
DRUG
Rituximab
Trial Locations (1)
20892
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00072592 - An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies | Biotech Hunter | Biotech Hunter